MONTREAL, CANADA – August 2nd, 2016 -S.I.F.I- Società Industria Farmaceutica Italiana S.p.A. (“SIFI”), a prominent Italian Eye Care company, and Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that they have entered into an agreement whereby Knight received the exclusive rights to commercialize NETILDEX™ in Canada. NETILDEX™ is a fixed combination of netilmicin and dexamethasone for the treatment of ocular inflammation of the anterior segment of the eye, in presence or at risk of bacterial infection. Under the terms of this agreement, Knight will also handle all ongoing regulatory and commercial activities for NETILDEX™ in Canada. Destum Partners acted as the advisor for SIFI on this agreement.
Innopharmax and Avir announce a License Agreement
[Times – Taipei] China (4172) signed licensing, supply and distribution agreements with Avir Pharma, Canada. For this reason, the contract sales region includes the sole agent of Canada, and Saudi Arabia, the United Arab Emirates, Qatar, Oman, Kuwait, Lebanon non-exclusive agent. The main terms of this contract, due to the development of China, production and supply responsibility; Avir Pharma marketing, distribution of drugs. The contract period is 7 years after the product is marketed. If the contract expires 2 years before the expiration of the contract, the contract will be renewed for 5 years, including the future supply conditions and authorization. (Edited by: Li Huilan)
Advaxis’ Axalimogene Filolisbac to be Developed and Commercialized in Latin America With Stendhal
PRINCETON, NJ, February 3, 2016 – Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it has entered into a co-development and commercialization agreement with Especificos Stendhal SA de CV (“Stendhal”), for Advaxis’ lead Lm Technology™ immunotherapy, axalimogene filolisbac (ADXS-HPV), in HPV-associated cancers. Stendhal is a privately held Latin American specialty pharmaceutical company that partners with leading drug companies to deliver effective solutions for life-threatening diseases in Latin American markets.